ORIGINAL RESEARCH article
Front. Immunol.
Sec. Parasite Immunology
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1641280
This article is part of the Research TopicInnovative Vaccine Development Strategies for Parasitic DiseasesView all articles
Controlled human malaria infection with NF54 and 7G8 strains elicit differential antibody responses to Plasmodium falciparum peptides
Provisionally accepted- 1Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, United States
- 2The Emmes Company LLC, Rockville, United States
- 3University of Maryland Baltimore Institute for Genome Sciences, Baltimore, United States
- 4Nimble Therapeutics Inc, Madison, United States
- 5National Institute of Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases, Bethesda, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Extensive Plasmodium falciparum genetic diversity plays a role in immune evasion, and antibody responses can be strain-specific or broadly reactive depending on the epitope. Controlled human malaria infection (CHMI) allows investigation of immune responses to variant parasite proteins after a single infection with a known strain.We designed a novel diversity-reflecting peptide microarray containing 638,817 unique peptides representing 22,655 variants of 227 proteins from 23 P. falciparum genome assemblies and 379 field isolates. Using this array, we probed sera from 38 malaria naïve adults before and 28 days after CHMI with one of two genetically distinct P. falciparum strains, NF54 (n = 21) or 7G8 (n = 17). We examined fold-increase in antibody response (intensity) and cross-reactivity to protein variants (breadth). ABCPred was used to predict linear epitopes for all 227 proteins. We used MEME to identify enriched motifs in regions of high intensity or breadth, which were presumed to be potential epitopes.Results: While the two CHMI groups had similar intensity of responses to all proteins on the array, 20 proteins on the array had differential breadth of responses and participants infected with 7G8 strain had a higher breadth of responses to 17 of them. Of 543 ABCPred-predicted epitopes, overlapped with MEME-identified epitopes, six of which were highly cross-reactive with >95% of peptide variants serorecognized by at least one CHMI group.Discussion: Overall, we found most antibody responses to be comparable after infection with the NF54 strain or 7G8 strain, but we saw notable differences for ~10% of proteins on the array. While many MEME-identified epitopes from highly cross-reactive proteins were asparagine rich, an epitope from PF3D7_1033200 (ETRAMP10.2) was not. Highly cross-reactive responses to ETRAMP10.2 could be further characterized and ETRAMP10.2 could be considered for inclusion in a next generation vaccine.
Keywords: Malaria, Plasmodium falciparum, Controlled human malaria infection, Peptide microarrays, humoral immunity to malaria, epitope
Received: 04 Jun 2025; Accepted: 12 Aug 2025.
Copyright: © 2025 Friedman-Klabanoff, Jensen, Lyke, Laurens, Carneiro da Silva, Stucke, Ouattara, Ifeonu, Hodges, Moser, Gelber, Goll, Patel, Pinapati, Tan, Deye, Harrison, Travassos and Berry. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Andrea A Berry, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.